Walleye Capital
CYTK icon

Walleye Capital’s Cytokinetics CYTK Stock Holding History

Walleye Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.71M Sell
25,900
-1,100
-4% -$69.9K 0.01% 1600
2025
Q4 		$1.72M Buy
27,000
+6,500
+32% +$404K 0.01% 1991
2025
Q3 		$1.13M Sell
20,500
-64,600
-76% -$2.66M ﹤0.01% 1996
2025
Q2 		$2.81M Buy
85,100
+64,800
+319% +$2.25M 0.01% 1257
2025
Q1 		$816K Buy
+20,300
New +$933K ﹤0.01% 2139
2024
Q3 		– Sell
-11,400
Closed -$618K – 5391
2024
Q2 		$618K Sell
11,400
-44,400
-80% -$2.68M ﹤0.01% 3325
2024
Q1 		$3.91M Buy
55,800
+54,300
+3,620% +$4.2M 0.01% 1482
2023
Q4 		$125K Sell
1,500
-18,100
-92% -$655K ﹤0.01% 3948
2023
Q3 		$577K Sell
19,600
-100
-0.5% -$3.33K ﹤0.01% 2705
2023
Q2 		$643K Buy
+19,700
New +$729K ﹤0.01% 2236
2023
Q1 		– Sell
-1,600
Closed -$73.3K – 4004
2022
Q4 		$73.3K Buy
1,600
+1,000
+167% +$43K ﹤0.01% 2442
2022
Q3 		$29K Buy
+600
New +$28.9K ﹤0.01% 2676
2020
Q2 		– Sell
-2,200
Closed -$26K – 674
2020
Q1 		$26K Buy
2,200
+500
+29% +$6.38K 0.01% 742
2019
Q4 		$18K Buy
+1,700
New +$17.5K ﹤0.01% 1613
2019
Q3 		– Sell
-9,800
Closed -$110K – 1952
2019
Q2 		$110K Buy
+9,800
New +$94.5K 0.01% 1192

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Walleye Capital's CYTK Position: Q1 2026 in Review

Walleye Capital sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 15,131 shares — an estimated $962K sold.

Walleye Capital first reported a position in CYTK in Q2 2019 and held it in 13 quarters. The position peaked at $9.81M in Q4 2022. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Walleye Capital reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 15,131 Cytokinetics shares in Q1 2026, an estimated $962K.
  • Walleye Capital first reported a position in Cytokinetics in Q2 2019 and held it in 13 quarters.
  • Walleye Capital's Cytokinetics position peaked at $9.81M in Q4 2022.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.